Company intelligence / Profile preview

Engage Bio

San Carlos, California, United Statesengagebio.com ↗

Ownership: Private
Employees: ~6
Development stage: Other

Overview

Engage Bio is developing novel mRNA and non-viral DNA platforms to deliver potent, durable, and redosable genetic medicines for cancer treatment. Their approach enables local production of immunotherapies within solid tumors to maximize efficacy while minimizing systemic toxicity. The company’s founders have experience with four drugs currently in clinical trials from previous roles, but Engage Bio’s own programs are preclinical as of the latest updates.

Therapeutic areas: Oncology
Modalities: mRNA-based drugsDNA medicine (non-viral DNA)
Industry: Biotech

Beyond the preview

Go deeper on Engage Bio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Engage Bio.

Explore the full profile